试验观察：血液系统肿瘤和实体瘤的溶瘤病毒免疫疗法
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
作者信息
Pol Jonathan G, Lévesque Sarah, Workenhe Samuel T, Gujar Shashi, Le Boeuf Fabrice, Clements Derek R, Fahrner Jean-Eudes, Fend Laetitia, Bell John C, Mossman Karen L, Fucikova Jitka, Spisek Radek, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo
机构信息
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
INSERM, Paris, France.
出版信息
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
Abstract
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.
摘要
溶瘤病毒以免疫原性方式选择性地靶向并杀死癌细胞，从而有助于建立具有治疗意义的肿瘤特异性免疫反应。2015年，美国食品药品监督管理局（FDA）批准溶瘤单纯疱疹病毒T-VEC用于晚期黑色素瘤患者。自那时起，已经开展了大量试验来评估多种溶瘤病毒在患有各种恶性肿瘤的患者中的安全性和有效性。在此，我们总结溶瘤病毒疗法领域最近的临床前和临床进展。
相似文献
1
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.试验观察：血液系统肿瘤和实体瘤的溶瘤病毒免疫疗法
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
2
Intratumoral Immunotherapy-Update 2019.肿瘤内免疫治疗-2019 更新。
Oncologist. 2020 Mar;25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438. Epub 2019 Nov 29.
3
Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives.日本的溶瘤病毒治疗：临床试验的进展和未来展望。
Jpn J Clin Oncol. 2019 Mar 1;49(3):201-209. doi: 10.1093/jjco/hyy170.
4
Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.新型溶瘤单纯疱疹病毒 1 VC2 在免疫活性 B16F10 衍生的小鼠黑素瘤模型中促进持久的、全身性抗黑素瘤肿瘤免疫反应和提高生存率。
J Virol. 2021 Jan 13;95(3). doi: 10.1128/JVI.01359-20.
5
Trial Watch-Oncolytic viruses and cancer therapy.试验观察——溶瘤病毒与癌症治疗
Oncoimmunology. 2015 Dec 8;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb.
6
Clinical advances in oncolytic virotherapy for pediatric brain tumors.小儿脑肿瘤溶瘤病毒治疗的临床进展。
Pharmacol Ther. 2022 Nov;239:108193. doi: 10.1016/j.pharmthera.2022.108193. Epub 2022 Apr 26.
7
The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers.溶瘤病毒在针对黑色素瘤、神经胶质瘤、胰腺癌和乳腺癌的临床试验中的现状与未来前景
Cancers (Basel). 2018 Sep 26;10(10):356. doi: 10.3390/cancers10100356.
8
Oncolytic virus therapy: A new era of cancer treatment at dawn.溶瘤病毒疗法：癌症治疗的新时代曙光初现。
Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9.
9
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.talimogene laherparepvec（T-VEC）及其他溶瘤病毒治疗黑色素瘤
Am J Clin Dermatol. 2017 Feb;18(1):1-15. doi: 10.1007/s40257-016-0238-9.
10
The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines.溶瘤单纯疱疹病毒 Talimogene Laherparepvec 在神经内分泌癌细胞系中显示出良好的疗效。
Neuroendocrinology. 2019;109(4):346-361. doi: 10.1159/000500159. Epub 2019 Jun 13.
引用本文的文献
1
Nanotechnology-enhanced immunotherapies for pancreatic ductal adenocarcinoma: challenges and opportunities.用于胰腺导管腺癌的纳米技术增强免疫疗法：挑战与机遇
Drug Deliv Transl Res. 2025 Jul 8. doi: 10.1007/s13346-025-01908-7.
2
Next-generation replication-defective HSV vectors for delivery of large DNA payloads.用于递送大型DNA载荷的下一代复制缺陷型单纯疱疹病毒载体。
Mol Ther. 2025 May 7;33(5):2205-2216. doi: 10.1016/j.ymthe.2025.03.055. Epub 2025 Apr 2.
3
Cell and gene therapy in neuro-oncology.神经肿瘤学中的细胞和基因治疗。
Handb Clin Neurol. 2024;205:297-315. doi: 10.1016/B978-0-323-90120-8.00009-5.
4
Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer.递送靶向癌症中PD-1/PD-L1免疫检查点的免疫疗法的替代策略
Pharmaceutics. 2024 Sep 7;16(9):1181. doi: 10.3390/pharmaceutics16091181.
5
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.教程：用于癌症免疫疗法的溶瘤病毒的设计、生产和测试。
Nat Protoc. 2024 Sep;19(9):2540-2570. doi: 10.1038/s41596-024-00985-1. Epub 2024 May 20.
6
Clinical Advances and Future Directions of Oncolytic Virotherapy for Head and Neck Cancer.头颈部癌溶瘤病毒疗法的临床进展与未来方向
Cancers (Basel). 2023 Nov 4;15(21):5291. doi: 10.3390/cancers15215291.
7
The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer.溶瘤单纯疱疹病毒1型（HSV-1）疫苗株VC2在四期乳腺癌的4T1/Balb/c小鼠模型中可引起功能活跃的T细胞在肿瘤内浸润，并抑制肿瘤转移以及肿瘤促发基因VEGF和PDL1的表达。
Front Mol Biosci. 2023 Jun 14;10:1199068. doi: 10.3389/fmolb.2023.1199068. eCollection 2023.
8
Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.柯萨奇病毒A21对耐药性肿瘤性B细胞的疗效。
Mol Ther Oncolytics. 2023 Mar 24;29:17-29. doi: 10.1016/j.omto.2023.03.002. eCollection 2023 Jun 15.
9
Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells.溶瘤性牛疱疹病毒1型足以诱导免疫原性细胞死亡，并与低剂量化疗协同作用以抑制免疫抑制性调节性T细胞。
Cancers (Basel). 2023 Feb 17;15(4):1295. doi: 10.3390/cancers15041295.
10
Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model.病毒疗法联合抗 PD-1 治疗在临床前 PDAC 模型中短暂重塑肿瘤免疫微环境并诱导抗肿瘤免疫。
Front Immunol. 2023 Jan 16;13:1096162. doi: 10.3389/fimmu.2022.1096162. eCollection 2022.
本文引用的文献
1
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.一项单中心II期试验，旨在评估TroVax®联合培美曲塞/顺铂对恶性胸膜间皮瘤患者的免疫活性——SKOPOS试验。
Oncoimmunology. 2018 Sep 7;7(12):e1457597. doi: 10.1080/2162402X.2018.1457597. eCollection 2018.
2
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.一种用于EGFR定向阻断PD-1/PD-L1免疫检查点的新型双特异性抗体。
Oncoimmunology. 2018 May 31;7(8):e1466016. doi: 10.1080/2162402X.2018.1466016. eCollection 2018.
3
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.一项关于solitomab（MT110，AMG 110）的多中心1期研究，solitomab是一种双特异性EpCAM/CD3 T细胞衔接器（BiTE®）抗体构建体，用于难治性实体瘤患者。
Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018.
4
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells.吉西他滨改变肿瘤细胞的蛋白酶体组成和免疫肽组。
Oncoimmunology. 2018 Mar 6;7(6):e1438107. doi: 10.1080/2162402X.2018.1438107. eCollection 2018.
5
Transforming the prostatic tumor microenvironment with oncolytic virotherapy.通过溶瘤病毒疗法改变前列腺肿瘤微环境。
Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.
6
Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma.基于抗CTLA-4的疗法在转移性黑色素瘤患者中引发了针对半乳糖凝集素-3的体液免疫。
Oncoimmunology. 2018 Mar 13;7(7):e1440930. doi: 10.1080/2162402X.2018.1440930. eCollection 2018.
7
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.接受PD-1阻断治疗的晚期实体瘤患者循环肿瘤细胞上PD-L1表达的动态变化
Oncoimmunology. 2018 Mar 6;7(7):e1438111. doi: 10.1080/2162402X.2018.1438111. eCollection 2018.
8
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.一项 EUS 引导下经皮肿瘤内注射溶瘤病毒 HF10 治疗不可切除局部进展期胰腺癌的 I 期临床试验。
BMC Cancer. 2018 May 25;18(1):596. doi: 10.1186/s12885-018-4453-z.
9
A Phase II Study of Pelareorep (REOLYSIN) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma.培拉罗力（瑞欧力辛）联合吉西他滨治疗晚期胰腺腺癌的II期研究。
Cancers (Basel). 2018 May 25;10(6):160. doi: 10.3390/cancers10060160.
10
Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.溶瘤性流感病毒感染可恢复肺肿瘤相关肺泡巨噬细胞的免疫活性。
Oncoimmunology. 2018 Feb 12;7(5):e1423171. doi: 10.1080/2162402X.2017.1423171. eCollection 2018.
Zotero 插件